Indian Immunologicals to invest Rs. 700 cr for new animal vax facility
To create employment for around 750 people
IIL MD Dr K Anand Kumar (L) with Telangana Industries Minister KT Rama Rao
IIL is on an aggressive growth path and this third vaccine facility in Hyderabad will ensure self-sufficiency for our nation in the field of vaccines and thereby saving the exchequer and farmers several thousands of crores
Hyderabad: Indian Immunologicals Ltd (IIL) announced that the company will invest about Rs 700 crore to set up a new animal vaccine manufacturing facility in Genome Valley in Hyderabad, called as the vaccine hub of the world, to meet the vaccine security of the nation against economically important diseases such as foot and mouth disease (FMD) and other emerging diseases.
On the occasion, Telangana Industries Minister KT Rama Rao said, "I'm delighted that IIL will be setting up another greenfield facility in Genome Valley. Hyderabad is already regarded as the Vaccine Capital of the World and this expansion further advances our contribution in terms of global health, not just for humans but also for animals".
The facility will create total employment for around 750 people. Dr K Anand Kumar, Managing Director of IIL, said: "IIL is on an aggressive growth path and this third vaccine facility in Hyderabad will ensure self-sufficiency for our nation in the field of vaccines and thereby saving the exchequer and farmers several thousands of crores."
IIL, a subsidiary National Dairy Development Board (NDDB) is already one of the largest manufacturers of FMD vaccine in the world and is the leading supplier of FMD vaccine to the Government of India's National Animal Disease Control Programme (NADCP). It is investing in a new greenfield project for the establishment of a Veterinary Vaccine Facility for manufacturing of FMD vaccine.
The new facility, in Genome Valley Phase 3, will add another 300 million doses/annum of FMD vaccine to its capacity. The existing facility in Gachibowli already has a capacity of 300 million doses. Production is scheduled to commence in the third year. The company is the market leader in veterinary and human biologicals in India. It manufactures over 150 products.
Genome Valley is home to more than 200 companies with a scientific workforce of about 15,000 professionals including presence of the marquee global names like Novartis, GlaxoSmithKline, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, Lonza amongst many others including other vaccines manufacturers like Bharat Biotech and Biological E.
